Agata Tyczyńska

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak et al. · The Lancet Oncology · 2023 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot et al. · New England Journal of Medicine · 2025 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge et al. · Blood · 2024 · 31 citations · Full text

Life Sciences, Biochemistry, Hematology +17

First‐line R‐CVP <i>versus</i> R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

Jan Walewski, Ewa Paszkiewicz‐Kozik, Wojciech Michalski et al. · British Journal of Haematology · 2019 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group

Grzegorz Charliński, Agata Tyczyńska, Bartosz Małecki et al. · Polskie Archiwum Medycyny Wewnętrznej · 2021 · 14 citations · Full text

Medicine, Hematology, Pharmacotherapy +12